DelveInsight’s, “Esophageal Cancer Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Esophageal Cancer pipeline landscape. It covers the Esophageal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Esophageal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Esophageal Cancer Pipeline Report

• DelveInsight’s Esophageal Cancer pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Esophageal Cancer treatment.
• The leading companies working in the Esophageal Cancer Market include BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier Inc., Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc.,, Adlai Nortye, Seagen, and others.
• Promising Esophageal Cancer Pipeline Therapies in the various stages of development include Nivolumab, Docetaxel/Paclitaxel, Leucovorin, Oxaliplatin, and others.
• November 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for pembrolizumab and Cisplatin. A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975).
• November 2023: Janssen Research & Development LLC announced a study of Phase 2 clinical trials for Erdafitinib. The primary purpose of this study is to evaluate objective response rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of erdafitinib in a molecularly-defined subset of Asian participants with non-small-cell lung cancer (NSCLC), urothelial cancer, esophageal cancer and cholangiocarcinoma.
• November 2023: Hoffmann- La Roche announced a study of Phase 3 clincial trials for Atezolizumab, Tiragolumab, and Paciltaxel. The purpose of this study is to evaluate the efficacy and safety of atezolizumab plus tiragolumab in combination with paclitaxel and cisplatin (PC) compared with atezolizumab matching placebo plus tiragolumab matching placebo plus PC as first-line treatment in participants with unresectable locally advanced, unresectable recurrent, or metastatic esophageal carcinoma (EC).

 

Request a sample and discover the recent advances in Esophageal Cancer Treatment Drugs @ Esophageal Cancer Pipeline Report

 

In the Esophageal Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Esophageal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Esophageal Cancer Overview

Esophageal cancer develops in the esophagus, which is the tube that connects throat to the stomach. Tumors arise in the mucosa, which is the inner lining of the esophagus. There are two types of esophageal cancer, each with different risk factors: Adenocarcinoma -Cancers that start in gland cells at the bottom of the esophagus are called adenocarcinomas. This type of cancer is the most common esophageal cancer.

 

Find out more about Esophageal Cancer Therapeutics Assessment @ Esophageal Cancer Preclinical and Discovery Stage Products

 

Esophageal Cancer Emerging Drugs Profile

• AN-0025: Adlai Nortye
• Tucatinib: Seagen
• APX 005M: Apexigen

 

Esophageal Cancer Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies for Esophageal Cancer. The Esophageal Cancer companies which have their Esophageal Cancer drug candidates in the most advanced stage, i.e. phase II/III include, Seagen.

 

DelveInsight’s Esophageal Cancer pipeline report covers around 80+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

Esophageal Cancer Pipeline Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

 

Learn more about the emerging Esophageal Cancer Pipeline Therapies @ Esophageal Cancer Clinical Trials Assessment

 

Scope of the Esophageal Cancer Pipeline Report

• Coverage- Global
• Esophageal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Esophageal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Esophageal Cancer Companies- BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier Inc., Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc.,, Adlai Nortye, Seagen, and others.
• Esophageal Cancer Pipeline Therapies in the various stages of development include Nivolumab, Docetaxel/Paclitaxel, Leucovorin, Oxaliplatin, and others.

 

Dive deep into rich insights for new drugs for Esophageal Cancer Treatment, Visit @ Esophageal Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Esophageal Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Esophageal Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. Drug Name : Company Name
9. Drug profiles in the detailed report…..
10. Last Stage Products (Phase II/III)
11. Tucatinib: Seagen
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. APX 005M: Apexigen
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name : Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Esophageal Cancer Key Companies
21. Esophageal Cancer Key Products
22. Esophageal Cancer – Unmet Needs
23. Esophageal Cancer – Market Drivers and Barriers
24. Esophageal Cancer – Future Perspectives and Conclusion
25. Esophageal Cancer Analyst Views
26. Esophageal Cancer Key Companies
27. Appendix

 

For further information on the Esophageal Cancer Pipeline therapeutics, reach out to Esophageal Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-market